JAK1 and dermatitis: Similarly, tofacitinib (JAK1/3) and oclacitinib (JAK1) inhibited the production of proinflammatory Th2 cytokines, including IL-4, in the toluene-2,4-diisocyanate (TDI) dermatitis model (19).